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Abstract: B-cell prolymphocytic leukemia (B-PLL) is a rare hematological disorder whose underlying
oncogenic mechanisms are poorly understood. Our cytogenetic and molecular assessment of 34 patients
with B-PLL revealed several disease-specific features and potential therapeutic targets. The karyotype
was complex (greater than or equal to3 abnormalities) in 73% of the patients and highly complex (5
abnormalities) in 45%. The most frequent chromosomal aberrations were translocations involving [t()]
(62%), deletion (del)17p (38%), trisomy (tri)18 (30%), del13q (29%), tri3 (24%), tri12 (24%), and del8p
(23%). Twenty-six of the 34 patients (76%) exhibit aberration, resulting from mutually exclusive translo-
cations or gains. Whole-exome sequencing revealed frequent mutations in , , , , , , , , and The majority of
B-PLL used the or subgroups (89%), and displayed significantly mutated genes (79%). We identified three
distinct cytogenetic risk groups: low-risk (no aberration), intermediate-risk ( aberration but no del17p),
and high-risk ( aberration and del17p) (p=.0006). drug response profiling revealed that the combination
of a B-cell receptor or BCL2 inhibitor with OTX015 (a bromodomain and extra-terminal motif (BET)
inhibitor targeting ) was associated with significantly lower viability of B-PLL cells harboring a t(). We
conclude that cytogenetic analysis is a useful diagnostic and prognostic tool in B-PLL. Targeting may be
a useful treatment option in this disease.
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Abstract:
B-cell prolymphocytic leukemia (B-PLL) is a rare hematological disorder whose underlying oncogenic mechanisms are poorly understood. Our
cytogenetic and molecular assessment of 34 patients with B-PLL revealed several disease-specific features and potential therapeutic targets.
The karyotype was complex (≥3 abnormalities) in 73% of the patients and highly complex (>5 abnormalities) in 45%. The most frequent
chromosomal aberrations were translocations involving MYC [t(MYC)] (62%), deletion (del)17p (38%), trisomy (tri)18 (30%), del13q (29%),
tri3 (24%), tri12 (24%), and del8p (23%). Twenty-six of the 34 patients (76%) exhibit MYC aberration, resulting from mutually exclusive
translocations or gains. Whole-exome sequencing revealed frequent mutations in TP53, MYD88, BCOR, MYC, SF3B1, SETD2, CHD2, CXCR4,
and BCLAF1. The majority of B-PLL used the IGHV3 or IGHV4 subgroups (89%), and displayed significantly mutated IGHV genes (79%). We
identified three distinct cytogenetic risk groups: low-risk (no MYC aberration), intermediate-risk (MYC aberration but no del17p), and high-risk
(MYC aberration and del17p) (p=.0006). In vitro drug response profiling revealed that the combination of a B-cell receptor or BCL2 inhibitor with
OTX015 (a bromodomain and extra-terminal motif (BET) inhibitor targeting MYC) was associated with significantly lower viability of B-PLL cells
harboring a t(MYC). We conclude that cytogenetic analysis is a useful diagnostic and prognostic tool in B-PLL. Targeting MYC may be a useful
treatment option in this disease.
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B-PLL is tightly linked to MYC aberrations (translocation or gain) and 17p (TP53) deletion. 
Cases of B-PLL with MYC aberration and 17p (TP53) deletion have the worst prognosis. 
Abstract 
B-cell prolymphocytic leukemia (B-PLL) is a rare hematological disorder whose underlying oncogenic 
mechanisms are poorly understood. Our cytogenetic and molecular assessment of 34 patients with 
B-PLL revealed several disease-specific features and potential therapeutic targets. The karyotype was 
complex (≥3 abnormalities) in 73% of the patients and highly complex (>5 abnormalities) in 45%. The 
most frequent chromosomal aberrations were translocations involving MYC [t(MYC)] (62%), deletion 
(del)17p (38%), trisomy (tri)18 (30%), del13q (29%), tri3 (24%), tri12 (24%), and del8p (23%). Twenty-
six of the 34 patients (76%) exhibit MYC aberration, resulting from mutually exclusive translocations 
or gains. Whole-exome sequencing revealed frequent mutations in TP53, MYD88, BCOR, MYC, SF3B1, 
SETD2, CHD2, CXCR4, and BCLAF1. The majority of B-PLL used the IGHV3 or IGHV4 subgroups (89%), 
and displayed significantly mutated IGHV genes (79%). We identified three distinct cytogenetic risk 
groups: low-risk (no MYC aberration), intermediate-risk (MYC aberration but no del17p), and high-
risk (MYC aberration and del17p) (p=.0006). In vitro drug response profiling revealed that the 
combination of a B-cell receptor or BCL2 inhibitor with OTX015 (a bromodomain and extra-terminal 
motif (BET) inhibitor targeting MYC) was associated with significantly lower viability of B-PLL cells 
harboring a t(MYC). We conclude that cytogenetic analysis is a useful diagnostic and prognostic tool 





























































































































B-cell prolymphocytic leukemia (B-PLL) is a very rare disease that accounts for less than 1% of all 
cases of chronic B-cell leukemia and generally occurs in elderly people. According to the World 
Health Organization (WHO) criteria, B-PLL can be diagnosed when prolymphocytes comprise more 
than 55% of the lymphoid cells in peripheral blood (PB). Diagnosis on the basis of clinical and 
morphological data can be difficult because B-PLL shares a number of features with other B-cell 
malignancies, including splenic marginal zone lymphoma (MZL), mantle-cell lymphoma (MCL) or 
chronic lymphocytic leukemia (CLL). For example, an unusual leukemic form of MCL mimicking B-PLL 
is distinguished by the presence of the t(11;14)(q13;q32) translocation
1,2
. B-PLL does not have a 
specific immunophenotype, and has low Matutes scores
3,4
, as observed for other B 
lymphoproliferative disorders.  
Little is known about the oncogenic events leading to the development and clinical heterogeneity of 
B-PLL. Given the disease’s rarity, its cytogenetic features have only been described in case reports 
and small series
5,6
, and large-scale genomic sequencing has not yet been performed for this disease.  
Rituximab-based chemo-immunotherapy is often used to treat patients with B-PLL but no TP53 
aberrations. In patients with TP53 aberrations, alemtuzumab-based regimens have been 
implemented. Lasting treatment responses are rare, and the prognosis is generally poor
7
. Recent 
data from case reports and small series suggest that two agents targeting B-cell signaling (ibrutinib 
and idelalisib) are efficacious
8-10
. Hence, allogeneic hematopoietic stem cell transplant is still the only 
curative treatment for B-PLL - albeit in younger patients only
7
.  
In the present study, we performed cytogenetic and molecular assessments in one of the largest 
reported series of patients with a validated diagnosis of B-PLL. Furthermore, we sought correlations 
between the cytogenetic and molecular findings and the patients’ clinical outcomes. Lastly, we 
studied the primary B-PLL cells’ in vitro response to novel targeted therapeutics. Overall, the present 
study is the first to have provided an extensive genetic portrait of B-PLL and to have offered insights 
into prognostic markers and treatment options. 
 
Patients, materials and methods 
Patient selection 
Databases from 28 French healthcare establishments were retrospectively screened for cases of de 






















































































































of 87 patients with an available blood smear at diagnosis were first identified locally, based on cell 
morphologic criteria. All 87 blood smears were blind-reviewed by three independent expert 
cytologists (LB, KM, and CS), and ten representative smears were subsequently reviewed further by a 
fourth cytologist (J-FL) (Supplementary information and Supplemental Table S1). Only 34 of the 87 
cases met the WHO criteria for B-PLL (i.e. prolymphocytes accounted for more than 55% of the 
lymphoid cells in PB). A diagnosis of MCL was ruled out by karyotyping (K) and FISH assays: no CCND1 
rearrangements or other infrequent translocations involving CCND2 and CCND3 were observed 
11,12
. 
Four other patients carrying a translocation t(11;14)(q13;q32) with a CCND1 rearrangement were 
diagnosed as having MCL and were excluded. Cytogenetic and molecular analyses were performed 
on the available material: at diagnosis for 21 patients, during follow-up and before treatment for 10 
(median time between diagnosis and sampling: 44 months), and at relapse for 3. The study was 
performed in accordance with the Declaration of Helsinki, and was approved by the local 
investigational review board (CPP-Ile-de-France VI, Paris, France) on May 21
th
, 2014.  
Karyotyping and FISH analysis 
Standard chromosome banding analyses were used to obtain R-or G-banded chromosomes from PB 
(n=28), bone marrow (n=4) or spleen (n=1). The samples were cultured for 48–72 hours with 12-O-
tetradecanoylphorbol-13-acetate (n=6) or CpG-oligonucleotides and interleukin 2 (n=27). All the K 
results were reviewed by the members of the Groupe Francophone de Cytogénétique Hématologique 
and classified according to the International System for Human Cytogenetic Nomenclature (ISCN 
2016). Complex Ks (CKs) and highly complex Ks (HCKs) were defined as the presence of at least three 
or five numerical or structural chromosomal abnormalities, respectively. Standard FISH was 
performed in all cases. The specific probes and procedures used are detailed in the supplementary 
information.  
Whole-exome sequencing 
DNA extracted from flow-sorted CD19+ tumor cells (and CD5+, IGL or IGK when appropriate) and 
non-tumor (CD3+) cells (considered to be germinal controls) was used for exome capture according 
to standard procedures. Paired-end sequencing was performed using HiSeq2000 sequencing 
instruments (Illumina, San Diego, CA). More detailed information can be found in the supplementary 
information.  
 
Targeted deep resequencing 
Mutation validation using targeted deep resequencing was performed as described previously
13
. 























































































































IGH rearrangements sequencing was performed on DNA extracted from sorted tumor cells or from 
whole blood, as described previously
14
. Depending on the % of identity of the IGHV genes with their 
germline counterparts, sequences were considered as unmutated (100% identity), 
minimally/borderline mutated (99.9%–97%) or significantly mutated (< 97% identity), following 
criteria proposed by Hadzidimitriou et al.
15
 for MCL and Bikos et al.
16
 for MZL. 
RNA Sequencing 
RNA sequencing was performed on high-quality RNA from 12 B-PLL as described previously
17
. More 
detailed information can be found in the supplementary information.  
In vitro cell viability and programmed cell death (PCD) assays 
The viability of primary B-PLL cells was assessed with the ATP-based CellTiter-Glo 2.0 assay (Promega, 
Madison, WI). Briefly, after pretreatment (or not) with the BET proteins inhibitors (iBET) OTX015 or 
JQ1 (500 nM), B-PLL cells were exposed for 48h to increasing concentrations of fludarabine, ibrutinib, 
idelalisib or venetoclax. Viability was determined by normalizing luminescence units against a DMSO 
control. Alternatively, PCD was measured by flow cytometry using annexin-V and propidium iodide 
co-labeling, after B-PLL cells treatment for 48h with ibrutinib, idelalisib, venetoclax, or OTX015. 




Overall survival (OS) was defined as the time interval between diagnosis and death or last follow-up. 
Categorical variables were compared using a chi-squared test or Fisher’s exact test, whereas 
continuous variables were compared using the Mann-Whitney test. Survival analyses were 
performed using the Kaplan-Meier method. The log-rank test was used for intergroup comparisons of 
OS curves. A 2-sided P < 0.05 was considered statistically significant. All statistical analyses were 
performed using MedCalc software (version 17.8.6, Ostend, Belgium). 
Accession Numbers 
The WES and RNA-Seq data have been deposited in the European Genome-phenome Archive (EGA) 
database (accession number EGAD00001002323, EGAD00001002438 and EGAD00001002476). 
 























































































































Characteristics of the study population 
The study included 34 patients diagnosed with de novo B-PLL between 1992 and 2017 (Table 1). 
There was a predominance of males (59%), and the median (range) age at diagnosis was 72 (46.2-
87.9). The median lymphocyte count was 36 G/L (4.6-244) and the median proportion of 
prolymphocytes was 79.5 (60-100). Nineteen of the 34 patients (56%) were positive for CD5 
(Supplemental Table S2). The median (range) follow-up time after diagnosis was 47 months (0.2-
141). Most of the patients had been treated (29/33, 88%) with a median (range) time after diagnosis 
of 3.2 months (0-106). 
Chromosomal aberrations: MYC is the most frequently altered gene in B-PLL 
Karyotype was performed in 33 patients (Table 1 and Supplemental Table S3). A CK was found in 73% 
of the patients, and HCK in 45%. By combining K and FISH data, we observed that the most frequent 
abnormality, found in 21 of the 34 patients (62%), was a translocation involving the MYC gene 
[t(MYC)]. This translocation involved the IGH locus in 12 cases, IGL in 6 and IGK in 1. The MYC gene 
partner was not identified in 2 cases. Five of the 34 patients (15%) had gained copies of the MYC 
gene: three had 3 copies, one had 4 copies and one had MYC amplification. Thus the majority of the 
cases (26 out of 34, 76%) had a MYC abnormality, MYC translocation and MYC gain being mutually 
exclusive. The other frequent chromosomal aberrations were: del17p including the TP53 gene 
(13/34, 38%), trisomy (tri) 18/18q (10/33, 30%), del13q (10/34, 29%), tri3 (8/33, 24%), tri12 (8/34, 
24%) and del8p (7/31, 23%) (Figure 1).  
An analysis of copy number values (calculated from the WES coverage in 16 patients) confirmed the 
majority of recurrent losses and gains observed by K and/or FISH analyses, and highlighted other 
novel recurrent copy number variations: losses of 5q22-23, 9q34, 14q24 and 19p13, and gains of 
17q24, 1q31-42 and 4q27-35 (Supplemental Table S4). 
 
IGHV analyses: preferential usage of VH3 and VH4 genes, and frequently mutated IGHV genes 
We obtained clonal IGH sequences in 19 B-PLL patients. In 17 of the 19 B-PLL cases (89%), a member 
of the IGHV3 (n=11, including 4 IGHV3-23) or IGHV4 (n=6) subgroups was involved, while the IGHV1 
subgroup gene (IGHV1-2) was used in the two remaining cases. Furthermore, the vast majority of B-
PLL sequences (15/19, 79%) displayed significantly mutated IGHV genes (Supplemental Table S5). 
 
The spectrum of somatic mutations 
WES of paired tumor-control DNA was performed in 16 patients and mutations were validated by 
targeted deep-resequencing and/or RNA-Seq (Supplemental Figure S1 and Supplemental Table S6). 






















































































































mutated gene was TP53, with a total of 7 mutations observed in 6 of the 16 patients (38%). These 
TP53 mutations were predicted to affect the protein's DNA binding domain (Supplemental Figure S2). 
In all cases, these mutations were associated with a del17p. Mutations in MYD88 were found in four 
patients. Interestingly, the MYD88 mutation was associated with tri3 in two cases, with a VAF of 
66.5% (BPLL_6) and 67.4% (BPLL_32) indicating that the mutated copy was duplicated. Mutations in 
genes that have a role in chromatin modifications were recurrent, including the X-linked BCOR gene 
encoding a BCL6 corepressor (n=4), CHD2 (n=2), SETD2 (n=2) and other genes mutated in one patient 
each: CREBBP, EZH2, KMT2D, NCOR1, SETD1B and TET2. The MYC gene had missense mutations in 3 
patients, all of whom harbored a t(MYC). Two mutations were just downstream of the transactivation 
domain, and one was in the bHLH domain (Supplemental Figure S2). The products of other relevant 
mutated genes were found to be involved in RNA metabolism (SF3B1, BCLAF1, ZRSR2 and WBP4), cell 
migration (CXCR4), cell cycle (CDKN3, RB1), apoptosis (TP73) and NOTCH signaling (NOTCH2 and 
FBXW7) (Figure 2). 
 
IGL/PVT1 fusions 
Using RNA-Seq, we detected IG fusion transcripts in 3 of 7 patients with t(MYC). In case #27 
harboring a t(8;14)(q24;q32), IGHG1 was fused with intron 1 of MYC. In cases BPLL_4 and BPLL_30 
with a t(8;22)(q24;q11), the PVT1 gene was fused to IGLL5 or IGLV4-69*01, respectively. The two 
latter fusions were confirmed by an RT-PCR assay. No other recurrent fusion transcripts were found 
in the 12 patients with RNA-Seq data (Supplemental Table S7). 
 
Clonal organization 
With a view to identifying early and late oncogenic events, we evaluated the clonal or subclonal 
nature of chromosomal abnormalities and recurrent somatic mutations. We observed that t(MYC), 
del17p, tri12 and mutations in the TP53, BCOR, MYC, SF3B1 and MYD88 genes were mostly clonal, 
and should be considered as early events in B-PLL. In contrast, MYC gain, del8p and del13q were 
frequently subclonal indicating that they are acquired (Supplemental Figure S3). 
 
Correlations between cytogenetic aberrations, mutations and gene expression patterns 
We identified three cytogenetic subgroups (Figure 1 and Table 3). The main subgroup of patients 
(21/34, 62%) had a t(MYC). Relative to the patients without t(MYC), this subgroup had a higher 
percentage of prolymphocytes  (p=.03), a higher proportion of CD38+ cells (p<.0001), a lower level of 
cytogenetic complexity (p=.0005), a lower proportion of cases with HCK (p=.0004), fewer unbalanced 
translocations (p=.04), and fewer cases with del17p (p=.0006). Mutations in MYC and in genes 






















































































































observed in the t(MYC) subgroup, whereas mutations in TP53 were less frequent (Figure 2A). A 
principal component analysis (PCA) of gene expression data from the 12 cases analyzed by RNA-Seq 
showed that the 7 patients with t(MYC) clustered together (Figure 2B). Taken as whole, these results 
suggest that patients with t(MYC) form a homogeneous subgroup of B-PLL. A second subgroup of B-
PLL with MYC gain (5/34, 15%) was associated with HCK (p=.01) and tri3 (p=.008). The remaining 8 
patients corresponded to a third subgroup lacking MYC aberration. Compared with patients with 
MYC aberration, this third subgroup had a lower percentage of prolymphocytes (p=.03), no CD38+ 
expression (p<.001), a higher number of chromosomal aberrations (p=.02) and a higher frequency of 
del17p (p=.03) (Table 3).  
 
Survival analyses: the prognostic values of MYC aberrations and del17p 
The median OS for the entire study cohort was 125.7 months. Patients with t(MYC) had a median 
[95% CI] OS of 57.5 months [25.7-132.1], which did not differ significantly from the value observed 
for patients with MYC gain (median: 66.5 months) (Figure 3A). Hence, we pooled patients with MYC 
aberration for subsequent OS comparisons, and found that they had a significantly shorter OS than 
patients without MYC aberrations (p=.03) (Figure 3B). 
With regard to the combination of MYC and del17p aberrations, we identified three distinct 
prognostic groups with significant differences in OS (p=.0006) (Figure 3C). The patients without MYC 
aberration (n=8) had the lower risk (median not reached). Patients with MYC aberration 
(translocation or gain) but no del17p (n=18) had an intermediate risk (125.7 months). The high-risk 
group corresponded to patients with both MYC and del17p (n=7, 11.1 months).  
Other chromosomal abnormalities and karyotype complexity did not have a significant impact on OS. 
Patients with del17p tended to have a shorter OS than those without (Supplemental Figure S4).  
 
In vitro drug response assays 
To evaluate the B-PLL cell's sensitivity to drugs used in the treatment of B-cell malignancies, we first 
used a cell viability assay based on the quantification of cellular ATP levels (an indicator of metabolic 
activity
18
) on primary B-PLL cells after 48h of exposure to ibrutinib, idelalisib (both B-cell receptor 
(BCR) inhibitors), venetoclax (a highly specific inhibitor of the anti-apoptotic protein BCL2), and 
fludarabine. The drugs were tested alone or in combination with OTX015 (an iBET known to suppress 
MYC expression in leukemia and lymphoma cell lines)
19-21
. Treatment with increasing doses of single 
drugs resulted in reduced cell viability in the 3 cases with t(MYC) (BPLL_8, BPLL_13 and BPLL_18), but 
varied from one drug to another and from one patient to another. Relative to treatments with single 






















































































































with a much lower level of viability (<30%) in patients with t(MYC) (Figure 4A). In contrast, the 
patient harboring a del17p but not a MYC aberration (BPLL_34) was significantly more resistant to 
single drugs and OTX015 co-treatments than patients with t(MYC) (Figure 4B). To confirm these 
results, we applied a complementary cytofluorometric approach. In BPLL_8 with t(MYC), treatments 
with drugs alone killed between 13 and 27% of the cells. An additive effect of OTX015 was observed; 
between 48 and 63% of the cells were killed (Figure 4C). Cells from patient BPLL_34 (del17p but no 
MYC aberration) were less sensitive to all drugs tested in both the presence and absence of OTX015 
(Figure 4D). Thus, the ATP assay and flow cytometry assay results highlighted the efficacy of 
combined drug + iBET treatment of cells from patients with t(MYC). The enhancing effect of the iBETs 
on the PCD induced by fludarabine, ibrutinib, and venetoclax was fully corroborated by the results of 
co-treatment with JQ1, another well-known iBET (Supplemental Figure S5B-C). It should be noted 




In the present study, we genetically characterized 34 patients with B-PLL. Given that the diagnosis of 
B-PLL is challenging, a thorough morphological review of blood smears was performed by three 
independent cytologists. Although we excluded patients with a history of MZL, the absence of a 
biopsy analysis means that we cannot fully rule out the possible presence of MZL with a 
prolymphocytoid transformation- an extremely rare situation 
22
. 
To the best of our knowledge, the present series is the largest yet to have undergone a 
comprehensive genomic characterization of B-PLL. We found that the most frequent aberrations are 
related to MYC alterations (in 77% of cases) highlighting the MYC’s major role in the pathogenesis of 
B-PLL. Strikingly, MYC translocations and MYC gain were found to be mutually exclusive. 
Translocations in which the MYC gene is repositioned under the control of an enhancer (usually 
immunoglobulin genes enhancers) result in the overexpression of MYC, as does the gain of one or 
more copies of MYC
23
. Although MYC translocations and mutations are classically associated with 
Burkitt lymphoma (BL), aberrations in MYC have also been linked to almost all B-cell neoplasms. With 
regard to B-PLL, MYC translocations and MYC gain have been reported in a few cases
24-29
. In the 
present series, t(MYC) was present in the major clone but MYC gain was mainly subclonal and/or 
overlooked as part of a CK. Thus, performing FISH with a specific probe is essential to identify MYC 
gain or amplification. We found MYC gene mutations in 3 cases, all of which also had t(MYC). These 
mutations were not located in the transactivation domain (the hot spot for MYC mutations in BL). 






















































































































by enhancing the oncogenicity of Myc
30
. We found a fusion transcript between PVT1 and an IGL gene 
in two patients with a variant MYC translocation t(8;22). This fusion subsequently disrupted the PVT1 
gene, a long intergenic noncoding RNA located 55 kb downstream of MYC, and which has been 
identified as a recurrent breakpoint in BL harboring variant translocations t(2;8) or t(8;22)
31,32
. In a 
recent study, the PVT1 promoter was found to behave like a tumor-suppressor DNA element: 
silencing the PVT1 promoter increased MYC transcription and cell proliferation
33
. As with MYC 
mutations, disruption of the PVT1 gene in some B-PLL patients might cooperate functionally with 
translocations to increase MYC-mediated oncogenesis. 
Our present results confirmed previous case reports in which a CK was frequent in B-PLL
24,27,34
. The 







), and CLL at diagnosis (15%
39-42
), and is similar to that observed in high-risk 
CLL
43
. Whereas t(MYC) is the main abnormality in B-PLL (62%), it is rare in other chronic B-cell 
disorders (i.e. below 5% in MCL, MZL and CLL
28,38,44
). The frequency of del17p in B-PLL (38%) observed 
here is higher than for MCL and MZL (both around 20%)
37,38
, or for CLL (5 to 7% at diagnosis)
39,45
. In 
addition to MYC and TP53 abnormalities, we found several other recurrent chromosomal aberrations 
in B-PLL, including trisomies 3, 12 and 18, del13q, and del8p. None of the chromosomal 
abnormalities observed in B-PLL are specific and so can be observed in other mature B-cell 
malignancies, albeit at different frequencies. Similarly, all the driver genes recurrently mutated in B-
PLL are also involved in other chronic B-cell disorders, but not with the same prevalence. In line with 
previous studies
5,6
, we found a high frequency of TP53 mutations (37.5%) in B-PLL; this frequency is 







 and BL (24%)
49
.  
We identified a high frequency of clonal BCOR mutations, which were only present in t(MYC) 
patients. BCOR encodes a Bcl6 co-repressor that silence BCL6 targets by epigenetic modifications
50
. 
Inactivating mutations of BCOR have been found in myeloid disorders
51,52
 but are very unusual in B-
cell diseases, except in the rare splenic diffuse red pulp lymphoma
53
. The association of BCOR 
mutations and t(MYC) might be a specific feature of B-PLL. Indeed, a recent study of Eμ-Myc 
lymphomas in a mouse model revealed a high frequency of Bcor mutations and showed that Bcor 




Our data showed that patients with B-PLL and t(MYC) form a homogeneous subgroup, with a less 
karyotype complexity, a higher proportion of prolymphocytes and a higher frequency of CD38 






















































































































some patients with t(MYC), suggesting oncogenic cooperation in the development of B-PLL. MYC 
aberration is a feature shared with BL, however, in contrast to BL, we did not find any mutation in 
TCF3, ID3 or CCND3 genes in B-PLL
49
.  
Van der Verlen et al. have suggested that B-PLL is a specific subgroup of t(11;14)-negative MCL, 
based on similarities in the immunophenotype, immunogenotype and gene expression profile
55
. We 
did not find any CCND1 or ATM mutations (the most frequent mutations in MCL
56
), in our patients 
with B-PLL. The vast majority of B-PLL expressed significantly mutated IGHV genes belonging to the 
IGHV3 and IGHV4 subgroups, in keeping with previous reports
57,58
. This contrasts with MCL, that 
exhibit predominantly no or minimal somatic hypermutations
15
. 
Taken as a whole, our data demonstrate that the genomic profile of B-PLL shares similarities with 
that of chronic B-cell malignancies but also displays unique combinations of alterations, thus 
confirming that B-PLL is a distinct entity. 
The median OS time in our cohort was 125.7 months - longer than the times reported in two earlier 
studies
6,59
. This difference might be due to our patients’ treatments with rituximab, alemtuzumab or 
fludarabine – all of which are reportedly efficacious in B-PLL60,61. In light of our results, we propose a 
hierarchical prognostic model that depends on MYC aberration (translocation or gain) and del17p. 
Patients without MYC aberration have indolent disease (regardless of their 17p status), whereas 
patients with MYC aberration have a significantly shorter OS time. A combination of MYC aberration 
and del17p confers the worse outcome, with a median OS of less than one year. By analogy with the 
“double-hit” form of CLL involving del17p and MYC gain43, these patients may be considered as 
having a very high-risk form of B-PLL. Due to the rarity of this disease, our data were obtained with a 
relatively small number of patients and so need to be confirmed in future studies. 
Our in vitro data showed that a combination of ibrutinib, idelalisib or venetoclax with OTX015 is more 
cytotoxic that the drugs used alone - especially in patients with MYC translocation. This is concordant 
with the known effects of OTX015, an inhibitor of the bromodomain-containing proteins BRD2, BRD3 
and BRD4. These proteins act as epigenetic readers and have an important role in the regulation of 
transcription and the modulation of oncogene expression. Like other iBETs, OTX015 strongly 
downregulates the transcription of genes regulated by superenhancers, such as MYC
20
. Current 
approaches to the treatment of B-PLL (like CLL) are based on del17p. However, our results strongly 
suggest that MYC should be taken into account, and could be targeted. OTX015 is already in Phase I 
clinical studies with a relatively good safety profile
62
; when combined with targeted drugs, it might 






















































































































further investigations with a larger number of patients (especially those with MYC gain) are required 
to make progress in this field. 
In conclusion, we found that patients with B-PLL have CKs and HCKs, a high frequency of MYC 
aberration (by translocation or gain), frequent del17p, and frequent mutations in the TP53, BCOR, 
MYD88 and MYC genes. We identified three prognostic subgroups, depending on MYC and 17p 
status. Patients with both MYC aberration and del17p had the shortest OS, and should be considered 
as a high-risk subgroup. Our results showed that cytogenetic analysis is a useful diagnostic and 
prognostic tool in B-PLL. We recommend K and FISH (for MYC and TP53) analyses whenever B-PLL is 
suspected. Moreover, our in vitro data strongly suggest that drugs targeting the BCR and BCL2 in 
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 Figures legends 
Tables 
Table 1. Characteristics of the patients with B-PLL 
Table 2. Recurrently mutated genes identified using WES in 16 patients with B-PLL 
Table 3. Comparison of the three cytogenetic subgroups (S): significant results 
 
Figures 
Figure 1. Distribution of chromosomal abnormalities detected in 34 patients with B-PLL: three 
cytogenetic subgroups of patients: MYC translocation, MYC gain, and no MYC aberration. Each 
column represents one patient, and each row one particular genetic or laboratory parameter. Color 
code: black or blue: presence; grey: absence; white: not available. CK: complex karyotype (three or 
more chromosomal abnormalities), HCK: highly complex karyotype (five or more chromosomal 
abnormalities), del: deletion, tri: trisomy. The percentages of prolymphocytes (indicated in black 
boxes) correspond to above-median values, relative to the cohort as a whole. 
Figure 2. Whole-exome sequencing and RNA-seq. A. Distribution of the chromosomal aberrations 
and mutations in the three cytogenetic subgroups (MYC translocation, MYC gain, and no MYC 
aberration) in the 16 cases analyzed using WES. Chromosomal abnormalities: grey: absence; color: 
presence. Mutations: grey: WT; color: mutated. B. Principal component analysis of differential gene 
expression patterns for 12 samples with various cytogenetic abnormalities. 
Figure 3. Overall survival in patients with B-PLL. (A) and (B) as a function of MYC aberrations 
(translocation (t(MYC) or gain) and the presence or absence of MYC aberration (ab); the t(MYC) and 
MYC gain data were pooled. (A) t(MYC) median [95%CI]: 57.5 months [25.7-132.1] vs MYC gain 
median [95%CI]: 66.5 months [4.7-undetermined]. (B) MYC aberration (t(MYC) + MYC gain) median 
[95%CI]: 57.5 [25.7-132.1]. (C) MYC and del17p status. MYC aberration without del17p median 
[95%CI]: 125.7 months [52.2-132.1]; MYC aberration with del17p median [95%CI]: 11.1 months [4.7-
66.5] 
Figure 4. The combination of drugs frequently used to treat B-cell malignancies with BET protein 
inhibitors enhances the killing of primary B-PLL cells with t(MYC). (A) B-PLL cells from 3 patients 
with t(MYC) were treated with the indicated concentrations of ibrutinib, idelalisib, venetoclax or 
fludarabine in the presence or absence of OTX015 (500 nM). Viability was assessed with an ATP-
based CellTiter-Glo® 2.0 kit. (B) B-PLL cell viability was measured and analyzed as in (A) in a patient 
with del17p but no MYC aberration. (C) Cell death was quantified in primary B-PLL cells from patient 






















































































































ibrutinib (7.5 µM), idelalisib (50 µM) or venetoclax (10 nM). The percentages refer to annexin-V-
positive or annexin-V-/PI-positive cells. (D) Primary B-PLL cells from BPLL_34 (with del17p but no 


























































































































Age at diagnosis, years (median, range) 72 [46.2-87.9] 
Sex (M/F) 20/14 
Splenomegaly 18/31 (58%) 
Lymphadenopathy 6/31 (19%) 
Lymphocytosis G/L (median, range) 36 [4.6-244] 
% of prolymphocytes (median, range) 79.5 [60-100] 
Treated patients 29/33 (88%) 
Death 14/33 (42%) 
Follow-up (median, range) 47 m [0,2-141] 
OS, median (95%CI) 125.7 m (52.3-132.1) 
TTT, median (95%CI) 5.8 m (1.5-27.5) 
CD38+ 20/33 (61%) 
Matutes' score  
0 8/33 (25%) 
1 11/33 (33%) 
2 9 (27%) 
3 5 (15%) 
CD5+ 19/34 (56%) 
CD23+ 11/34 (32%) 
CK >3 abnormalities* 24/33 (73%) 
HCK >5 abnormalities* 15/33 (45%) 
Number of karyotypic aberrations  (median, range)* 4 [1-21] 
Unbalanced translocations* 23/33 (70%) 






















































































































del17p (TP53) 13/34 (38%) 
Tri12 8/34 (24%) 
Tri3 8/33 (24%) 
Tri18 10/33 (30%) 
MYC gain 5/34 (15%) 
del13q 10/34 (29%) 
del8p (TNFRSF10) 7/31 (23%) 
IGHV mutated 16/19 (84%) 
TP53 mutated 6/16 (38%) 
MYD88 mutated 4/16 (25%) 
BCOR mutated 4/16 (25%) 
MYC mutated 3/16 (19%) 
SF3B1 mutated 3/16 (19%) 
 
Table 1. Characteristics of the patients with B-PLL 
m: months; OS: overall survival; TTT: time to first treatment; t(MYC): translocation involving 
MYC;CK: complex karyotype; HCK: highly complex karyotype; del: deletion; tri: trisomy. 
*The frequency of chromosomal abnormalities did not differ significantly when comparing 


































































































































p.V132L, T205C, V236G, 
A248D, L275Q, R282P 
Cell cycle, apoptosis 
MYD88 
(NM_002468) 









3 3 V160L, S161L, F389L Cell cycle 
SF3B1 
(NM_012433) 

















2 2 S338X, S325Qfs*22 Cell migration 
BCLAF1 
(NM_001077440) 
2 2 R820C, W211X RNA processing factor 
NFASC 
(NM_001005388) 
2 2 T946I, V644M Neuronal development 
 






































































































































86% (61-100) 79 (66-91) 76% (60-80) 
S1 vs S2+S3 
S3 vs S1+S2 
.03 
.03 
CD38+ 18/20 (90%) 2/5 (40%) 0/8 (0%) 
S1 vs S2+S3 







3 (1-9) 6 (5-21) 10 (1-15) 
S1 vs S2+S3 
S3 vs S1+S2 
.0005 
.02 
HCK >5 4/20 (20%) 5/5 (100%) 6/8 (75%) 
S1 vs S2+S3 





11/20 (55%) 5/5 (100%) 7/8 (88%) S1 vs S2+S3 .04 
del17p 3/21 (14%) 4/5 (80%) 6/8 (75%) 
S1 vs S2+S3 
S3 vs S1+S2 
.0006 
.03 
Tri3 4/20 (20%) 4/5 (80%) 0/8 (0%) S2 vs S1+S3 .008 
 
Table 3. Comparison of the three cytogenetic subgroups (S) (MYC translocation, MYC gain, without 
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